Partners and Founders
- Joan Bigorra
Director of innovation at Hospital Clinic of Barcelona (www.hospitalclinic.org). Masters in Biomedicine, Biotechnology and EU law from the NED. MD and PhD from the Autonomous University of Barcelona (clinical pharmacology), graduate in Biostatistics (UAB), Health Economics (University of Thromso) and General Management (IESE, Harvard Business School). Before joining Hospital Clinic, Dr. Bigorra has developed his professional career in Pharmaceutical industry, being Medical Director at Bayer, Boheringer Inghelheim and General Manager at Novartis Spain.
- Michelle Messmer
Director of Customer Programs and Health Care Professional Programs in Italian Multiple Sclerosis Society, responsible for managing the strategic and operational plan for programs involving people with MS and their families, as well as the Professional Education Program MS Society. Member of the International Organization of Multiple Sclerosis Nurses (IOMSM), the Consortium of Centers Multiple Sclerosis (CMSMS), the International Certification Board of Nursing in Multiple Sclerosis (earthquakes). Also MS in Focus is editor of the international journal of MSFI (International Federation of Multiple Sclerosis).
- Joaquim Trias
Joaquim Trias Puig-Sureda is one of the top names in the American biotech sector with more than 20 years experience in biotech development at Silicon Valley. He has helped found companies like Microcide Pharmaceuticals, Vicuron (acquired by Pfizer), Peninsula (bought by Johnson&Johnson), Anthera and Tetraphase.
- Larry Steinman
MD Harvard University, NIH Fellow at Harvard Medical School, and currently Professor, Departments of Neurology and Neurological Sciences, Stanford University.
He has obtained several awards and prizes like Senator Jacob Javits Neuroscience Investigator Award, Congress of the United States and NIH or Charcot Award for Lifetime Achievement in MS Research, International Federation of MS Societies (2011). Co-Inventor of leading MS drug Natalizumab and several new therapies for autoimmune diseases (eg. DNA vaccination)
- Craig Smith
MD University of Washington, Professor of Medicine, Neurology, Ophthalmology and Neurosurgery at the University of Washington up until 2004. Currently Chief Medical Officer in an innovation biotech company.
Led the anti-CD20 teams in Genentech that developed a body of evidence-based medicine redefining the immunology of T/B-cell interactions in MS. Following Genentech, took over as Clinical Science Unit Head, Ophthalmology and eHealth Global Strategic Lead, Novartis.
- Steve Hauser
MD Harvard Medical School and currently Professor and Chair, Department of Neurology, UCSF.
He has received numerous awards and honors for his work, including the Jacob Javits Neuroscience Investigator Award and the John Dystel Prize for Multiple Sclerosis Research. Responsible for one of the first clinical trials of immunosuppression on the course of progressive MS. Dr. Hauser has been appointed by President Obama to the Presidential Commission for the Study of Bioethical Issues charged with advising the President on issues that may emerge from advances in biomedicine and related areas of science and technology.